Find Flutemetamol manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

16RELATED EXCIPIENT COMPANIES

33EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Exclusivities

0

Health Canada Patents

API REF. PRICE (USD/KG)

$
$ 0

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

API

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Flutemetamol f 18, Vizamyl, Flutemetamol (18f), 18f-flutemetamol, Flutemetamol f18, Flutemetamol ((sup18)f)
Molecular Formula
C14H11FN2OS
Molecular Weight
273.32  g/mol
InChI Key
VVECGOCJFKTUAX-HUYCHCPVSA-N
FDA UNII
L49M066S0O

Flutemetamol
Flutemetamol F 18 is a radiopharmaceutical containing flutemetamol, a thioflavin derivative of Pittsburgh compound B (PiB) labeled with the radioisotope fluorine F18 that can be used to detect beta-amyloid deposition upon positron emission tomography (PET). After intravenous administration of flutemetamol F 18, the flutemetamol moiety selectively accumulates in and binds to cerebral fibrillar amyloid-beta in the brain. The fluorine F18 radioisotope moiety is detected using PET, which allows imaging and quantification of amyloid-beta density. Amyloid plaque deposition is linked to cognitive decline, including Alzheimer's disease, and may be linked to chemotherapy-induced cognitive impairment (CICI).
Flutemetamol f-18 is a Radioactive Diagnostic Agent. The mechanism of action of flutemetamol f-18 is as a Radiopharmaceutical Activity.
1 2D Structure

Flutemetamol

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
2-[3-(18F)fluoranyl-4-(methylamino)phenyl]-1,3-benzothiazol-6-ol
2.1.2 InChI
InChI=1S/C14H11FN2OS/c1-16-11-4-2-8(6-10(11)15)14-17-12-5-3-9(18)7-13(12)19-14/h2-7,16,18H,1H3/i15-1
2.1.3 InChI Key
VVECGOCJFKTUAX-HUYCHCPVSA-N
2.1.4 Canonical SMILES
CNC1=C(C=C(C=C1)C2=NC3=C(S2)C=C(C=C3)O)F
2.1.5 Isomeric SMILES
CNC1=C(C=C(C=C1)C2=NC3=C(S2)C=C(C=C3)O)[18F]
2.2 Other Identifiers
2.2.1 UNII
L49M066S0O
2.3 Synonyms
2.3.1 MeSH Synonyms

1. (18f)flutemetamol

2. Flutemetamol

3. Vizamyl

2.3.2 Depositor-Supplied Synonyms

1. Flutemetamol F 18

2. Vizamyl

3. Flutemetamol (18f)

4. 18f-flutemetamol

5. Flutemetamol F18

6. Flutemetamol ((sup18)f)

7. 765922-62-1

8. [18f]flutemetamol

9. Flutemetamol F 18 [usan]

10. Flutemetamol (18f) [inn]

11. Chebi:76611

12. L49m066s0o

13. (18f)flutemetamol

14. (18f)ah110690

15. 2-(3-(sup 18)f)fluoro-4-(methylamino)phenyl)-1,3-benzothiazol-6-ol

16. Flutemetamol F 18 (usan)

17. 2-[3-(18f)fluoro-4-(methylamino)phenyl]-1,3-benzothiazol-6-ol

18. 2-[3-(18f)fluoranyl-4-(methylamino)phenyl]-1,3-benzothiazol-6-ol

19. [18f]ah110690

20. Flutemetamol ((sup 18)f)

21. Unii-l49m066s0o

22. Vizamyl (tn)

23. [18f]-flutemetamol

24. Flutemetamol ((18)f)

25. [18f]-flutemetamol F18

26. Gtpl7342

27. Chembl2042122

28. Schembl10032147

29. (18f)flutemetamol [mi]

30. Dtxsid80227394

31. ((18 Sup)f)ah110690

32. Db09151

33. Flutemetamol (18f) [who-dd]

34. Flutemetamol F-18 [orange Book]

35. Ah-110690 F-18

36. D10231

37. Q18355673

38. 2-[3-((18)f)fluoro-4-(methylamino)phenyl]-1,3-benzothiazol-6-ol

39. 2-(3-((18 Sup)f)fluoro-4-(methylamino)phenyl)-1,3-benzothiazol-6-ol

40. 6-benzothiazolol, 2-(3-(fluoro-(sup 18)f)-4-(methylamino)phenyl)-

2.4 Create Date
2007-03-07
3 Chemical and Physical Properties
Molecular Weight 273.32 g/mol
Molecular Formula C14H11FN2OS
XLogP33.8
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count5
Rotatable Bond Count2
Exact Mass273.060146 g/mol
Monoisotopic Mass273.060146 g/mol
Topological Polar Surface Area73.4 Ų
Heavy Atom Count19
Formal Charge0
Complexity320
Isotope Atom Count1
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NameVizamyl
PubMed HealthFlutemetamol F 18 (Injection)
Drug ClassesDiagnostic Agent
Drug LabelVizamyl contains flutemetamol F 18, a molecular imaging agent that binds to -amyloid aggregates, and is intended for use with PET imaging of the brain. Chemically, flutemetamol F 18, is described as 2-[3-[18F]fluoro-4-(methylamino) phenyl]-6-benzot...
Active IngredientFlutemetamol f-18
Dosage FormInjectable
RouteIntravenous
Strength40.5mci/10ml (4.05mci/ml); 121.5mci/30ml (4.05mci/ml)
Market StatusPrescription
CompanyGe Healthcare

2 of 2  
Drug NameVizamyl
PubMed HealthFlutemetamol F 18 (Injection)
Drug ClassesDiagnostic Agent
Drug LabelVizamyl contains flutemetamol F 18, a molecular imaging agent that binds to -amyloid aggregates, and is intended for use with PET imaging of the brain. Chemically, flutemetamol F 18, is described as 2-[3-[18F]fluoro-4-(methylamino) phenyl]-6-benzot...
Active IngredientFlutemetamol f-18
Dosage FormInjectable
RouteIntravenous
Strength40.5mci/10ml (4.05mci/ml); 121.5mci/30ml (4.05mci/ml)
Market StatusPrescription
CompanyGe Healthcare

4.2 Drug Indication

Flutemetamol F18 is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) or other causes of cognitive decline.


FDA Label


This medicinal product is for diagnostic use only.

Vizamyl is a radiopharmaceutical medicinal product indicated for Positron Emission Tomography (PET) imaging of amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimers disease (AD) and other causes of cognitive impairment. Vizamyl should be used in conjunction with a clinical evaluation.

A negative scan indicates sparse or no plaques, which is not consistent with a diagnosis of AD.


5 Pharmacology and Biochemistry
5.1 Pharmacology

Following intravenous injection, flutemetamol F 18 diffuses across the human blood-brain barrier and produces a radioactivity signal detectable throughout the brain. Subsequently, cerebral perfusion decreases the brain flutemetamol F 18 content, with differential retention of the drug in cortical areas that contain -amyloid aggregates compared to areas that lack the aggregates.


5.2 MeSH Pharmacological Classification

Contrast Media

Substances used to allow enhanced visualization of tissues. (See all compounds classified as Contrast Media.)


Radiopharmaceuticals

Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161) (See all compounds classified as Radiopharmaceuticals.)


5.3 FDA Pharmacological Classification
5.3.1 Active Moiety
FLUTEMETAMOL F-18
5.3.2 FDA UNII
L49M066S0O
5.3.3 Pharmacological Classes
Radiopharmaceutical Activity [MoA]; Radioactive Diagnostic Agent [EPC]
5.4 ATC Code

V09AX04


V09AX04

S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355


V - Various

V09 - Diagnostic radiopharmaceuticals

V09A - Central nervous system

V09AX - Other central nervous system diagnostic radiopharmaceuticals

V09AX04 - Flutemetamol (18F)


5.5 Absorption, Distribution and Excretion

Absorption

The time-activity curves for flutemetamol F 18 in the brain of subjects with positive scans shows continual signal increases from time zero through 30 minutes post administration, with stable values thereafter up to at least 120 minutes post-injection. Following intravenous injection of 185 MBq (5 mCi) of Vizamyl in humans, flutemetamol F 18 plasma concentrations declined by approximately 75% in the first 20 minutes post-injection, and by approximately 90% in the first 180 minutes.


Route of Elimination

Excretion was found to be approximately 37% renal and 52% hepatobiliary.


5.6 Metabolism/Metabolites

The F 18 in circulation during the 30-120 minutes imaging window in plasma was principally associated with flutemetamol metabolites.


5.7 Mechanism of Action

Fluorine-18 (F 18) is a cyclotron-produced radionuclide that decays by positron emission (+ decay, 96.7%) and orbital electron capture (3.3%) to stable oxygen-18 with a physical half-life of 109.8 minutes. The positron can undergo annihilation with an electron to produce two gamma rays; the energy of each gamma ray is 511 keV. After flumetamol F18 is given intravenously, it accumulates in beta amyloid plaques in the brain, and thus becomes visible via positron emission tomography (PET).


Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Solubilizers

read-more
read-more

Parenteral

read-more
read-more

Emulsifying Agents

read-more
read-more

Topical

read-more
read-more

Surfactant & Foaming Agents

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Direct Compression

read-more
read-more

Rheology Modifiers

read-more
read-more

API Stability Enhancers

read-more
read-more

Co-Processed Excipients

read-more
read-more

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 765922-62-1 / Flutemetamol API manufacturers, exporters & distributors?

Flutemetamol manufacturers, exporters & distributors 1

22

PharmaCompass offers a list of Flutemetamol API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Flutemetamol manufacturer or Flutemetamol supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Flutemetamol manufacturer or Flutemetamol supplier.

PharmaCompass also assists you with knowing the Flutemetamol API Price utilized in the formulation of products. Flutemetamol API Price is not always fixed or binding as the Flutemetamol Price is obtained through a variety of data sources. The Flutemetamol Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Flutemetamol

Synonyms

Flutemetamol f 18, Vizamyl, Flutemetamol (18f), 18f-flutemetamol, Flutemetamol f18, Flutemetamol ((sup18)f)

Cas Number

765922-62-1

Unique Ingredient Identifier (UNII)

L49M066S0O

About Flutemetamol

Flutemetamol F 18 is a radiopharmaceutical containing flutemetamol, a thioflavin derivative of Pittsburgh compound B (PiB) labeled with the radioisotope fluorine F18 that can be used to detect beta-amyloid deposition upon positron emission tomography (PET). After intravenous administration of flutemetamol F 18, the flutemetamol moiety selectively accumulates in and binds to cerebral fibrillar amyloid-beta in the brain. The fluorine F18 radioisotope moiety is detected using PET, which allows imaging and quantification of amyloid-beta density. Amyloid plaque deposition is linked to cognitive decline, including Alzheimer's disease, and may be linked to chemotherapy-induced cognitive impairment (CICI).

Flutemetamol Manufacturers

A Flutemetamol manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Flutemetamol, including repackagers and relabelers. The FDA regulates Flutemetamol manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Flutemetamol API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

Flutemetamol Suppliers

A Flutemetamol supplier is an individual or a company that provides Flutemetamol active pharmaceutical ingredient (API) or Flutemetamol finished formulations upon request. The Flutemetamol suppliers may include Flutemetamol API manufacturers, exporters, distributors and traders.

Flutemetamol GMP

Flutemetamol Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Flutemetamol GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Flutemetamol GMP manufacturer or Flutemetamol GMP API supplier for your needs.

Flutemetamol CoA

A Flutemetamol CoA (Certificate of Analysis) is a formal document that attests to Flutemetamol's compliance with Flutemetamol specifications and serves as a tool for batch-level quality control.

Flutemetamol CoA mostly includes findings from lab analyses of a specific batch. For each Flutemetamol CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Flutemetamol may be tested according to a variety of international standards, such as European Pharmacopoeia (Flutemetamol EP), Flutemetamol JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Flutemetamol USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty